This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
Delivered as Hybrid Event from 15-18 November 2022
Live In-Person Conference Delivered 15-18 NovemberAustria Center Vienna

Michael Skynner, Ph.D.
Chief Operating Officer at Bicycle Therapeutics


Michael Skynner, Ph.D., is chief operating officer at Bicycle Therapeutics responsible for global operations, the platform, discovery and strategic alliances. He has over 22 years of pharm/biotech experience and joined Bicycle in 2016 from Pfizer, where he led rare disease efforts in Europe and founded both the Pfizer Rare Disease Consortium & Genetic Medicine Institute. Previously, he established a discovery performance unit at GSK focused on developing clinical small-molecule therapeutics targeting inflammatory kinases. Prior to GSK he co-founded a successful peptide-based biotech start-up company, Cambridge Biotechnology Ltd., which was sold to Swedish Orphan Biovitrum.

Agenda Sessions

  • Bi-cyclic Peptide (Bicycle®) Mediated Delivery of RNA-targeted Therapeutics